GlassScriptPhysician profile
Muhammad Saad Hamid
NPI 1508276916
$1,838.78
in general payments reported to CMS, 2019-2025
23 companies · $21.91 in 2025
The $21.91 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2021: $90.84 · 2022: $102 · 2023: $612 · 2024: $347 · 2025: $21.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $508 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $229 · Travel and Lodging: $109 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $91.46 · Education: $44.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $507.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $228.66 |
| Travel and Lodging | $109.11 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $91.46 |
| Education | $44.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $359.68 | 2023-2025 | |
| Astellas Pharma US INC | $194.00 | 2019 | |
| Amgen INC. | $171.51 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $130.76 | 2019-2024 | Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $110.50 | 2019 | |
| Acrotech Biopharma INC. | $106.96 | 2024 | Beleodaq |
| Genentech USA, INC. | $99.95 | 2019 | |
| Alexion Pharmaceuticals, INC. | $99.00 | 2019 | |
| Taiho Oncology, INC. | $91.46 | 2023 | |
| Abbvie INC. | $56.90 | 2024 | |
| Kyowa Kirin, INC. | $51.23 | 2022-2024 | Poteligeo |
| Genmab U.S., INC. | $47.10 | 2023-2024 | Epkinly |
| Janssen Pharmaceuticals, INC | $45.35 | 2021-2022 | |
| Lilly USA, LLC | $44.16 | 2023 | |
| Janssen Scientific Affairs, LLC | $39.99 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $39.02 | 2021-2023 | |
| Celgene Corporation | $38.55 | 2023 | Opdualag, Pomalyst |
| Genzyme Corporation | $26.44 | 2023 | |
| Adaptive Biotechnologies Corporation | $24.27 | 2024 | Clonoseq |
| Exelixis INC. | $17.91 | 2023 | Cabometyx |
| Nestle Healthcare Nutrition INC. | $15.41 | 2023 | |
| Blueprint Medicines Corporation | $14.57 | 2022 | |
| Mylan Institutional INC. | $14.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Hamid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.